Loading company…
ONCOZEN develops oncology therapies that target and degrade disease-causing proteins.
ONCOZEN develops cancer and rare disease therapies using the body's Ubiquitin Proteasome System to target and degrade proteins associated with disease. The company is based in Cheongju, South Korea, and was founded in 2020 by Joo-hoon Ahn. It raised KRW 1 billion in pre-Series A funding from BNC Korea on April 19, 2022.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in